Stay updated with breaking news from Tom Graney. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Oxurion NV, Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Leuven, BELGIUM, Boston, MA, US - MAY 24, 2022 - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies,
Investegate announcements from Oxurion NV, Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)
Oxurion NV's proposed drug for diabetic macular edema failed to demonstrate efficacy on key endpoints based on top line results from its Phase II trial.